Cipla vs Fortis Healthcare Q3 FY26

Cipla's Q3 FY26 revenue was flat YoY at INR 7,074 crore, with EBITDA margin of 17.7% (down ~150-200bps vs internal expectations) due to lower generic revenues and elevated R&D spend (7% of sales, +37% YoY). PAT of INR 676 crore included a one-time INR 276 crore labor code charge. U.S. revenue fell to $167 million as Lenalidomide tapered and lanreotide supply was disrupted (partner Pharmathen paused production after FDA observations; resupply expected H1 FY27). India business grew 10% YoY, with respiratory crossing INR 5,000 crore. FY26 EBITDA margin guidance revised to ~21%. Key upcoming U.S. launches (4 respiratory, 4 peptide assets) are expected to offset revenue declines, but near-term headwinds persist. Risk: lanreotide disruption may extend beyond H1 FY27 if remediation is delayed.

Guidance read

FY26 EBITDA margin guidance revised to ~21%: Management lowered FY26 EBITDA margin guidance to ~21% from earlier expectations, citing lower lanreotide and Lenalidomide impact. U.S. launches: 4 respiratory and 4 peptide assets in FY27: Pipeline includes generic Advair, two other large respiratory assets (likely Symbicort), and three peptide launches including generic Victoza. Lanreotide resupply expected in H1 FY27: Partner Pharmathen paused production; resupply expected in H1 FY27, with alternate site evaluation underway. FY27 guidance to be provided next quarter: Management will provide FY27 guidance after finalizing the annual operating plan.

Risk read

Key risks include Lanreotide supply disruption may extend beyond H1 FY27 — Pharmathen's manufacturing pause and 483 observations could delay resupply, impacting U.S. revenue.; U.S. launch pipeline may face delays or competition — Respiratory and peptide launches are critical to offset Lenalidomide decline; any delay or increased competition could pressure revenue.; Elevated R&D spend may persist, pressuring margins — R&D at 7% of revenue is above historical 5-6% range; management expects normalization but lumpy spending could continue.; Semaglutide generic launch could impact tirzepatide uptake — Analyst questioned whether Cipla's agreement with Lilly restricts entry into semaglutide; management was evasive..

Promise ledger

Of 1 tracked promise, management 0 met, 0 close, 1 missed.

FO

Fortis Healthcare

Q3 FY26 · Healthcare

Fortis Healthcare delivered a strong Q3 FY26 with consolidated revenue of ₹2,265 crore (+17.5% YoY) and EBITDA margin expansion of 290 bps to 22.3%, driven by hospital business growth of 19.4% and diagnostics margin recovery to 23.1%. PAT declined to ₹197 crore due to a one-off expense of ₹55 crore for new labor codes. Hospital occupancy remained steady at 67%, while ARPOB grew 4.5% to ₹2.56 lakh, supported by a 52% surge in robotic surgeries. The diagnostics business saw 8.3% revenue growth and a 870 bps margin improvement. Management guided for continued growth trajectory with brownfield expansion of ~400 beds in FY27, led by the fMRI facility. The People Tree acquisition in Bengaluru adds 125 beds with expansion potential to 300. Risks include integration challenges at Glenagles and potential dilution from IHH's planned equity infusion.

Guidance read

Brownfield bed addition of ~400 beds in FY27: Major contribution from fMRI expansion (200+ beds) to be commissioned in phases starting April 2026. ARPOB growth of 4-5% annually for next 2 years: Driven by ~2.5% price increase and balance from case mix improvement, especially in oncology. Continued margin improvement trajectory for at least 2 years: Supported by brownfield expansions in high-margin facilities like fMRI and operational leverage. Potential equity infusion by IHH within 3-6 months: Preferential allotment likely after cooling period ends in May 2026, to strengthen balance sheet for growth.

Risk read

Key risks include Glenagles integration challenges — Revenue declined 4% in 9M FY26 due to management changes and operational issues; turnaround expected only from next fiscal.; Intense competition in Hyderabad cluster — Management expressed caution about Hyderabad due to competitive intensity, though it remains a focus cluster.; Execution risk in People Tree ramp-up — Acquired hospital is suboptimal and requires investment; expansion to 300 beds may take 30 months due to Bangalore approval delays.; CGHS/ECHS rate hike benefits uncertain — New circulars have implementation ambiguities; full benefit may be delayed until clarity on super-specialty rates and drug pricing..

Promise ledger

Scorecard data is being built as historical quarters are processed.